A few months ago, Human Genome Services Inc. (NASDAQ: HGSI) and co-development partner GlaxoSmithKline revealed data from a phase III trial of Benlysta™, a promising new drug for treating systemic lupus erythematosus (SLE), otherwise known as “lupus.” Their stock had literally tripled within a matter of two open trading sessions drawing significant attention from investors […]

Indianapolis-based pharmaceutical giant Eli Lilly & Co. have recently received approval from the FDA for using Alimta (a drug originally approved in 2004 for the treatment of mesothelioma) for maintenance therapy of advanced/metastatic non-smell cell lung cancer (NSCLC).

A recent Institute of Cancer Research study published in the New England Journal of Medicine describes a novel way of treating BRCA-gene based cancers. Mutations in the BRCA-1 and BRCA-2 genes are routinely linked with higher incidence of breast and ovarian cancers in women; however, in healthy cells, the aforementioned genes are involved in a […]

Those with stakes in GlaxoSmithKline (NYSE: GSK) were pleased this morning as the stock rose on account of the FDA’s approval of Lamictal XR (“extended release”) . The drug, aimed at epilepsy patients thirteen years of age and older, is intended to reduce seizures in patients who have had unsuccessful results with other therapies.